Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
Nearly two decades ago, the promise of precision medicine began making its mark on the pages of medical journals – along with speculation that “therapy with the right drug at the right dose in the right patient” – would define the future of medical treatment.
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
Shares of Bristol-Myers Squibb climbed after announcing its anticipated Phase III CheckMate-227 study met its endpoints of progression-free survival as a first-line lung cancer treatment.
EGP-437 demonstrated better clinical performance than vehicle control, but did not meet its co-primary endpoints.
Scholar Rock – a biotechnology company focused on discovering and developing drugs that selectively target growth factors in the disease microenvironment – announced the publication of “Blocking extracellular activation of myostatin as a strategy for treating muscle wasting,” in Scientific Reports, the peer-reviewed, open-access journal published by Nature.
Anika announced a research collaboration with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy for osteoarthritis.
First reported by FierceBiotech, Roche’s financial reports indicated the company was cutting a total of four drugs: One late-stage product and three drugs in Phase I development.
Researchers in Japan and Australia say they have made important progress in developing a blood test that could in future help doctors detect who might go on to get Alzheimer’s disease.
Vertex Pharmaceuticals selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients.
The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.
Bellicum Pharmaceuticals Inc. said the FDA placed a clinical hold on U.S. trials of the company’s experimental cancer drug after three cases of brain disease linked to head trauma.
Cancer patients’ survival prospects are improving – even for some of the deadliest types such as lung cancer – but there are huge disparities between countries, particularly for children, according to a published study.
Pfizer released an update of the company’s pipeline, including eight different discontinued projects in the field of neuroscience.
Eisai and Boston University School of Medicine Announce Research Collaboration to Study the Effects of Alzheimer’s Disease-associated Genetic Variants on Brain
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.
Corbus Pharmaceuticals Holdings Inc said the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function.
Scientists have assembled the most complete human genome to be mapped with a single technology using a new pocket-size portable DNA sequencer, which they say could one day make genome mapping quick and simple enough to do at home.
AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late-stage trial that could challenge GlaxoSmithKline’s new three-in-one inhaler.
Seniors who get a flu shot every year are less likely to be hospitalized with severe influenza infections or to die from them than those who get vaccinated only sporadically, a study suggests.
Takeda Pharmaceutical and development partner Zinfandel Pharmaceuticals pulled the plug on their five-year Phase III TOMMORROW trial following an interim analysis.
Pfizer Inc. announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera (rituximab-EU), met its primary endpoint.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage clinical trials.